Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials

Shi, Yetan; Si, Yue-Xiu; Fu, Rongrong; Zhang, Mengting; Jiang, Ke; Dai, Wei; Shen, Jingyi; Li, Xiangyuan; Yuan, Yuan

doi:10.5603/ep.a2021.0102

Cited by 8 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2022 ), and SGLT-2 inhibitors are associated with urinary or reproductive system infections (Shi et al. 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy

Ni,

Wu,

Yao

et al. 2024

Pharmaceutical Biology

View full text Add to dashboard Cite

Context The global prevalence of type 2 diabetes mellitus (T2DM) has increased significantly in recent decades. Despite numerous studies and systematic reviews, there is a gap in comprehensive and up-to-date evaluations in this rapidly evolving field. Objective This review provides a comprehensive and current overview of the efficacy of Traditional Chinese Medicine (TCM) in treating T2DM. Methods A systematic review was conducted using PubMed, Web of Science, Wanfang Data, CNKI, and Medline databases, with a search timeframe extending up to November 2023. The search strategy involved a combination of subject terms and free words in English, including ‘Diabetes,’ ‘Traditional Chinese Medicine,’ ‘TCM,’ ‘Hypoglycemic Effect,’ ‘Clinical Trial,’ and ‘Randomized Controlled Trial.’ The studies were rigorously screened by two investigators, with a third investigator reviewing and approving the final selection based on inclusion and exclusion criteria. Results A total of 108 relevant papers were systematically reviewed. The findings suggest that TCMs not only demonstrate clinical efficacy comparable to existing Western medications in managing hypoglycemia but also offer fewer adverse effects and a multitarget therapeutic approach. Five main biological mechanisms through which TCM treats diabetes were identified: improving glucose transport and utilization, improving glycogen metabolism, promoting GLP-1 release, protecting pancreatic islets from damage, and improving intestinal flora. Conclusions TCM has demonstrated significant protective effects against diabetes and presents a viable option for the prevention and treatment of T2DM. These findings support the further exploration and integration of TCM into broader diabetes management strategies.

show abstract

“… 2022 ), and SGLT-2 inhibitors are associated with urinary or reproductive system infections (Shi et al. 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy

Ni,

Wu,

Yao

et al. 2024

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…SGLT2Is reduced weight and waist circumference in overweight or obese patients without diabetes compared with those in the control group (other drugs or placebo), according to a systematic review (13 studies) ( 29 ). The mean body weight loss due to SGLT2Is in this population was -1.62 kg compared with that in the placebo group, and the BMI decreased by -0.47 kg/m 2 , which was superior to the placebo, according to a meta-analysis (5 clinical trials) ( 30 ).…”

Section: Metabolic Dysfunctions In Patients Undergoing Antipsychotic ...mentioning

confidence: 99%

Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)

Vasiliu¹

2023

Exp Ther Med

View full text Add to dashboard Cite

Metabolic dysfunctions have been reported in patients diagnosed with severe mental illnesses who are undergoing treatment with antipsychotics, especially second-generation agents. Sodium-glucose co-transporter 2 inhibitors (SGLT2Is) and glucagon-like peptide receptor agonists are new-generation antidiabetics whose favourable effects in the treatment of diabetes mellitus in the non-psychiatric population may raise interest in their use in patients presenting with severe mental illnesses and metabolic comorbidities possibly related to the use of antipsychotics. The objectives of this review were to investigate the evidence to support the use of SGLT2Is in this population and to find the most important aspects that need to be addressed by future research. A total of one preclinical trial, two guideline-format clinical recommendations, one systematic review and one case report were found, and their conclusions were analysed. The results support the following conclusions: i) SGLT2Is may be combined with metformin in selected cases of type 2 diabetes mellitus in the context of antipsychotic treatment, as they have been associated with favourable metabolic effects; and ii) data for the recommendation of SGLT2Is as second-line treatment in patients with diabetes mellitus who are also treated with olanzapine or clozapine are supported by very limited preclinical and clinical evidence. Further high-quality, large-scale research is needed in the field of the management of metabolic dysfunctions in patients with severe psychiatric illnesses who undergo treatment with second-generation antipsychotics. Contents1. Metabolic dysfunctions in patients undergoing antipsychotic treatment: General considerations 2. Objectives and methods of the review 3. Results Conclusions and clinical observations

show abstract

“…After 24 weeks of treatment, there were small yet statistically significant differences in waist circumference observed between the study groups (Bays et al, 2020) [4] . 2 meta-analyses have found that SGLT-2 inhibitors reduced weight in obese nondiabetic patients (Shi et al, 2022;Zheng et al, 2021) [28,32] .…”

Section: Sodium-glucose Cotransporter (Sglt) Inhibitorsmentioning

confidence: 99%

Pharmacotherapeutics efficacy in obesity treatment: A systematic review

BA,

HF,

et al. 2023

Int. J. Adv. Community Med.

View full text Add to dashboard Cite

Introduction: Obesity is a public health concern on a global scale, obesity can lead to significant risk of developing various comorbidities. Lifestyle interventions along with surgical and medical approaches are the primary options for obesity treatment. This systematic review aims to evaluate the efficacy and safety of pharmacological interventions for weight loss in adults with obesity. Methods: A systematic search review was carried out from January 2018 to December 2022. The search for relevant articles was conducted through PubMed and EBSCO databases. 2290 articles were retrieved and evaluated based on the established inclusion and exclusion criteria. Among them, 362 articles were duplicates and subsequently removed. Further, 1893 articles failed to meet the inclusion criteria and were excluded from this review. Consequently, 35 articles were considered for the review. Results: Pharmacologic interventions showed good efficacy in treating obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists showed the highest efficacy. Other options including sodium glucose cotransporter (SGLT) Inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, Gelesis100 also demonstrated efficacy to various degrees. The safety profile of these interventions was generally good with gastrointestinal symptoms being the most frequently reported adverse events in almost all the included interventions. Neurological symptoms were the most frequently reported in phentermine/topiramate. Conclusion: This review, in agreement with prior research, indicates that medications can effectively treat obesity with a favorable safety profile. Thus, pharmacotherapy presents a promising, safe, and effective method to achieve weight loss, indicating its potential to play a significant role in the future.

show abstract

Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials

Cited by 8 publications

References 33 publications

Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy

Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy

Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second‑generation antipsychotics (Review)

Pharmacotherapeutics efficacy in obesity treatment: A systematic review

Contact Info

Product

Resources

About